ClinicalTrials.gg
CompletedNCT04893707Updated Nov 8, 2024

The Study of CM310 in Patients With Atopic Dermatitis

A Phase 2 interventional study of CM310 in Moderate-to-severe Atopic Dermatitis, sponsored by Keymed Biosciences Co.Ltd. Completed at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-11-08.

Sponsored by Keymed Biosciences Co.Ltd · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
127
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 12 studies testing stapokibart in Dermatitis, Atopic — 2 open to participants now, 3 under way, 3 of them phase 3. stapokibart · Dermatitis, Atopic.

Enrollment
8th of 12
127 · median 170
Started
2021
with 1 other
Phase 2
5 of 12
none open now
Registered
3rd of 12
by date
Lead sponsor
12 of 12
Keymed Biosciences Co.Ltd

Among the 12 studies testing stapokibart in Dermatitis, Atopic, this one is the 8th largest by enrollment, is one of 2 that started in 2021, is one of 5 in phase 2, and was the 3rd registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

2 of the 12 studies testing stapokibart in Dermatitis, Atopic are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

About stapokibart

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 195 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 96 (49%) stop at 75 or younger; 94 take children under 18; 52 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing stapokibart in Dermatitis, Atopic, or all of them as a file.
02

Study summary

This is an open, multicenter, extension study evaluating the safety and efficacy of CM310 for long-term treatment in patients with atopic dermatitis The primary objective is to assess the long-term safety of CM310 administered in patients with atopic dermatitis (AD).

Read the detailed description

The secondary objective of the study is to assess the immunogenicity of CM310 in patients with AD, in the context of re-treatment, and to monitor efficacy parameters associated with long-term treatment.

03

Conditions studied

  • Moderate-to-severe Atopic Dermatitis

Browse trials for

Keywords

  • Atopic Dermatitis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participation in a prior clinical trial of CM310 for AD(CM310AD001 and CM310AD002) and met one of the following:

    1. Participation in CM310AD001:received study treatment and adequately completed the assessments and completed the EOS(D85±7) visit.
    2. Participation in CM310AD002 and met one of the following:i: Received study treatment and adequately completed the assessments and completed the EOS(V12) visit. ii:Treatment termination due to other reasons other than poor compliance or AE related to CM310 , completed the EOS visit .
  2. Provide signed

Exclusion criteria

Exclusion Criteria:

  1. Patients who, during their participation in a previous CM310 clinical trial, developed a SAE/AE deemed related to dupilumab*, which in the opinion of the investigator or of the medical monitor could not suitable to continue the treatment with CM310.
  2. Not enough washing-out period for previous therapy.
  3. Pregnancy.
  4. Other
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
127 participants (actual)

Study arms

  • Experimental
    CM310

    adults and teenagers (12 \~ 18 years) with weight ≥60 kg : 600mg for 1st dose, and then 300 mg, every 2 weeks and up to 1 year, SC. teenagers (12 \~ 18 years) with weight ≥30 kg and \<60kg : 400mg for 1st dose, and then 200 mg, every 2 weeks and up to 1 year, SC.

    Biological: CM310

Interventions

  • BiologicalCM310

    adults and teenagers (12 \~ 18 years) with weight ≥60 kg : 600mg for 1st dose, and then 300 mg, every 2 weeks and up to 1 year, SC. teenagers (12 \~ 18 years) with weight ≥30 kg and \<60kg : 400mg for 1st dose, and then 200 mg, every 2 weeks and up to 1 year, SC.

    Also known as: IL-4Rα monoclonal antibody

06

What researchers measure

Primary outcomes

  1. Number of Treatment Emergent Adverse Events (TEAEs)

    The primary endpoint in the study is the incidence and rate (events per patient-year) of TEAEs

    Time frame: Up to 2 Years

Secondary outcomes

  1. Number of Serious Adverse Events (SAEs) and Adverse Event of special interest(AESI)

    Incidence and rate (events per patient-year) of SAEs and AESIs

    Time frame: Up to 2 Years

  2. Proportion of patients with Eczema Area and Severity Index (EASI)-75 (≥75 percent reduction in EASI scores from baseline of the parent study) at each visit

    The EASI score was used to measure the severity and extent of atopic dermatitis (AD) and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 to 72 points, with the higher scores reflecting the worse severity of AD

    Time frame: Up to 2 Years

  3. Proportion of patients with Investigator's Global Assessment (IGA) score = 0-1 and decline ≥2 points from baseline at each visit

    Proportion of patients who achieve and maintain a score of 0 to 1 on the IGA scale \[(a 6-point scale ranging from 0 (clear) to 5 (very severe)\]

    Time frame: Up to 2 Years

  4. Proportion of patients with Eczema Area and Severity Index (EASI)-90 (≥90 percent reduction in EASI scores from baseline of the parent study) at each visit

    The EASI score was used to measure the severity and extent of atopic dermatitis (AD) and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 to 72 points, with the higher scores reflecting the worse severity of AD

    Time frame: Up to 2 Years

  5. Proportion of patients with Eczema Area and Severity Index (EASI)-50 (≥50 percent reduction in EASI scores from baseline of the parent study) at each visit

    The EASI score was used to measure the severity and extent of atopic dermatitis (AD) and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 to 72 points, with the higher scores reflecting the worse severity of AD

    Time frame: Up to 2 Years

  6. Change from baseline in EASI score at each visit

    The EASI score was used to measure the severity and extent of atopic dermatitis (AD) and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 to 72 points, with the higher scores reflecting the worse severity of AD

    Time frame: Up to 2 Years

  7. Proportion of patients with Investigator's Global Assessment (IGA) score = 0-1 at each visit

    IGA is a 6-point scale ranging from 0 (clear) to 5 (very severe)

    Time frame: Up to 2 Years

  8. Proportion of patients with IGA reduction from baseline of ≥2 points at each visit

    IGA is a 6-point scale ranging from 0 (clear) to 5 (very severe)

    Time frame: Up to 2 Years

  9. Proportion of patients with reduction of Pruritus Numerical Rating Scale (NRS) of ≥4 points from baseline

    Proportion of subjects with improvement (reduction) of pruritus NRS of ≥4 points from baseline. The range of NRS is from 0 (no itch)-10 (worst imaginable itch)

    Time frame: Up to 2 Years

  10. Proportion of patients with reduction of Pruritus Numerical Rating Scale (NRS) of ≥3 points from baseline

    The range of NRS is from 0 (no itch)-10 (worst imaginable itch)

    Time frame: Up to 2 Years

  11. Percent change from baseline in NRS

    The range of NRS is from 0 (no itch)-10 (worst imaginable itch)

    Time frame: Up to 2 Years

  12. Body Surface Area (BSA)

    Change from baseline in percent of BSA

    Time frame: Up to 2 Years

  13. Time to first remission (achieving IGA = 0 or 1)

    Time frame: Up to 2 Years

  14. Time to first relapse (eg, IGA >2) after remission or to not achieving remission

    Time frame: Up to 2 Years

  15. Time to first EASI-50/75/90

    Time frame: Up to 2 Years

  16. Proportion of patients requiring rescue treatment: Overall/Systemic treatment/Immunosuppressor/Systemic treatment

    Time frame: Up to 2 Years

  17. Number of days on topical medication (per patient-year)

    Time frame: Up to 2 Years

  18. Changes from baseline to prespecified time points through the end of the study: Dermatology Life Quality Index (DLQI)

    The DLQI is a 10-item, validated questionnaire used in clinical practice and clinical trials to assess the impact of AD disease symptoms and treatment on quality of life (QOL) (Badia 1999). The format is a simple response to 10 items, which assess QOL over the past week, with an overall scoring system of 0 to 30; a high score is indicative of a poor QOL

    Time frame: Up to 2 Years

  19. immunogenicity

    Detection of anti-drug antibody (ADA)

    Time frame: Up to 2 Years

  20. Pharmacokinetics parameters

    trough concentration of CM310

    Time frame: Up to 2 Years

07

Study locations

1 site
  • Peking University People's hospital
    Beijing, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2021 to primary completion in Feb 2023, 19 months.

Of 195 industry-sponsored phase 2 interventional studies under Dermatitis, Atopic, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 17. This study's 19 months is above that.

Counting every sponsor, half of 223 studies reached it within 14 months; a quarter within 10 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
May 15, 2021
First posted
May 19, 2021
StartActual
Jun 7, 2021
Primary completionActual
Feb 3, 2023
CompletionActual
Feb 3, 2023
Last update
Nov 8, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 8, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04893707
Responsible party
Sponsor
First posted
May 19, 2021
Start date
Jun 7, 2021
Primary completion
Feb 3, 2023
Completion
Feb 3, 2023
Last update
Nov 8, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Stapokibart

Start the discussion